ATHA/ 12/18/2025 · 10:10 AM Athira Pharma Secures $236M for Breakthrough Breast Cancer Treatment Athira Pharma acquires lasofoxifene drug rights and raises $236M to advance Phase 3 trials for ESR1-mutant metastatic breast cancer treatment through 2027.